



26 465.1861 Ordering and dispensing HIV infection prevention  
 27 drugs.—

28 (1) As used in this section, the term:

29 (a) "HIV" means the human immunodeficiency virus.

30 (b) "HIV infection prevention drug" means preexposure  
 31 prophylaxis, postexposure prophylaxis, and any other drug  
 32 approved by the United States Food and Drug Administration for  
 33 the prevention of HIV infection.

34 (c) "Postexposure prophylaxis" means a drug or drug  
 35 combination that meets the clinical eligibility recommendations  
 36 of the United States Centers for Disease Control and Prevention  
 37 guidelines for antiretroviral treatment following potential  
 38 exposure to HIV.

39 (d) "Preexposure prophylaxis" means a drug or drug  
 40 combination that meets the clinical eligibility recommendations  
 41 of the United States Centers for Disease Control and Prevention  
 42 guidelines for antiretroviral treatment for the prevention of  
 43 HIV transmission.

44 (2) A pharmacist may screen for HIV exposure and order and  
 45 dispense HIV infection prevention drugs in accordance with a  
 46 written protocol between the pharmacist and a supervising  
 47 physician or a statewide drug therapy protocol developed  
 48 pursuant to subsection (4).

49 (3) Before ordering or dispensing HIV infection prevention  
 50 drugs under this section, a pharmacist must be certified by the

51 board, according to the rules adopted by the board, in  
52 consultation with the Board of Medicine and the Board of  
53 Osteopathic Medicine. To be certified, a pharmacist must, at a  
54 minimum, meet all of the following criteria:

55 (a) Hold an active and unencumbered license to practice  
56 pharmacy under this chapter.

57 (b) Be engaged in the active practice of pharmacy.

58 (c) Have earned a doctorate of pharmacy degree or have  
59 completed at least 5 years of experience as a licensed  
60 pharmacist.

61 (d) Maintain at least \$250,000 of liability coverage. A  
62 pharmacist who maintains liability coverage pursuant to s.  
63 465.1865 or s. 465.1895 satisfies this requirement.

64 (e) Have completed a course approved by the board, in  
65 consultation with the Board of Medicine and the Board of  
66 Osteopathic Medicine, which includes, at a minimum, instruction  
67 on all of the following:

68 1. Performance of patient assessments.

69 2. Point-of-care testing procedures.

70 3. Safe and effective treatment of HIV exposure with HIV  
71 infection prevention drugs.

72 4. Identification of contraindications.

73 (4) The board, in consultation with the Board of Medicine,  
74 the Board of Osteopathic Medicine, and the department, shall  
75 develop a statewide drug therapy protocol for pharmacists to

76 test or screen for HIV exposure and order and dispense HIV  
 77 infection prevention drugs. In development of the statewide drug  
 78 therapy protocol, the board must consider, at a minimum, all of  
 79 the following:

80 (a) Physician referrals.

81 (b) Lab testing, including prescribing HIV preexposure and  
 82 postexposure screening tests.

83 (c) Appropriate referrals consistent with guidelines of  
 84 the United States Centers for Disease Control and Prevention.

85 (d) Counseling consistent with guidelines of the United  
 86 States Centers for Disease Control and Prevention.

87 (e) Patient follow-up care and counseling.

88 (5) The board shall adopt rules to implement this section,  
 89 including rules that establish protocols for ordering and  
 90 dispensing HIV infection prevention drugs.

91 Section 2. This act shall take effect July 1, 2024.